Research programme: coronavirus inhibitors - Kucera
Alternative Names: Coronavirus inhibitors research programme - KuceraLatest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Kucera Pharmaceutical
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Severe acute respiratory syndrome
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Severe acute respiratory syndrome in USA
- 08 Mar 2004 Preclinical trials in Severe acute respiratory syndrome in USA (unspecified route)